Recurrent herpes zoster after COVID‐19 vaccination in patients with chronic urticaria being treated with cyclosporine—A report of 3 cases

Mohta, Alpana; Arora, Aakanksha; Srinivasa, R; Mehta, Rajesh Dutt

doi:10.1111/jocd.14437

Cited by 21 publications

(7 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A total of 314 studies were identified. After applying the inclusion and exclusion criteria, 55 studies [11] , [12] , [13] , [14] , [15] , [16] , [17] , [18] , [19] , [20] , [21] , [22] , [23] , [24] , [25] , [26] , [27] , [28] , [29] , [30] , [31] , [32] , [33] , [34] , [35] , [36] , [37] , [38] , [39] , [40] , [41] , [42] , [43] , [44] , [45] , [46] , [47] , [48] , [49] , [50] , [51] , [52] , [53] , [54] , [55] , [56] , [57] , [58] , [59] , [60] , [61] , [62] , [63] , [64] , [65] of VZV manifestations in subjects with SARS-CoV-2 vaccinations or COVID-19 disease were deemed eligible for inclusion. A flow diagram of the selection of the studies is presented in Fig.…”

Section: Resultsmentioning

confidence: 99%

Varicella-Zoster virus reactivation following severe acute respiratory syndrome coronavirus 2 vaccination or infection: New insights

Martinez-Reviejo¹,

Adebanjo²,

Chello³

et al. 2022

European Journal of Internal Medicine

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Varicella-Zoster virus reactivation following severe acute respiratory syndrome coronavirus 2 vaccination or infection: New insights

Martinez-Reviejo¹,

Adebanjo²,

Chello³

et al. 2022

European Journal of Internal Medicine

View full text Add to dashboard Cite

“…psoriasis, 103 , 133 , 137 , 141 , 215 , 239 , 248 , 252 , 282 , 312 bullous pemphigoid, 63 , 111 pemphigus vulgaris, 111 , 121 lichen planus, 85 , 164 , 245 cutaneous vasculitis, 163 vitiligo 293 and cutaneous lupus erythematosus 156 , 188 , 236 ) and viral reactivation (e.g. herpes zoster 74 , 81 , 85 , 92 , 99 , 100 , 102 , 107 , 108 , 113 , 116 , 131 , 191 , 268 ). In addition, more severe but rare reactions such as anaphylaxis 15 , 37 , 38 , 40 , 41 , 44 , 123 and severe cutaneous adverse reactions (SCARs) 136 , 185 , 231 , 271 have been reported as well.…”

Section: Discussionmentioning

confidence: 99%

Global prevalence and clinical manifestations of cutaneous adverse reactions following COVID‐19 vaccination: A systematic review and meta‐analysis

Washrawirul

Triwatcharikorn

Phannajit

et al. 2022

Acad Dermatol Venereol

View full text Add to dashboard Cite

Although vaccination is widely accepted as an effective method of preventing and controlling the COVID‐19 pandemic, many people are concerned about possible cutaneous side‐effects, which can delay or prevent them from being vaccinated. The objectives of this systematic review were to assess the global prevalence and clinical manifestations of cutaneous adverse reactions following COVID‐19 vaccination. PubMed and Scopus databases were searched for articles published from 1 January 2019 to 31 December 2021, and reference lists for each selected article were screened. Case reports, case series, observational studies and randomized controlled trials that provided information on cutaneous adverse reactions following COVID‐19 vaccines were included. A total of 300 studies were included in a systematic review of which 32 studies with 946 366 participants were included in the meta‐analysis. The pooled prevalence of cutaneous manifestations following COVID‐19 vaccination was 3.8% (95% CI, 2.7%–5.3%). COVID‐19 vaccines based on the mRNA platform had a higher prevalence than other platforms at 6.9% (95% CI, 3.8%–12.3%). Various cutaneous manifestations have been reported from injection site reactions, which were the most common (72.16%) to uncommon adverse reactions such as delayed inflammatory reactions to tissue filler (0.07%) and flares of pre‐existing dermatoses (0.07%). Severe cutaneous reactions such as anaphylaxis have also been reported, but in rare cases (0.05%). In conclusion, cutaneous adverse reactions are common, especially in those receiving mRNA vaccines. Most reactions are mild and are not contraindications to subsequent vaccination except for anaphylaxis, which rarely occurs. COVID‐19 vaccination may also be associated with flares of pre‐existing dermatoses and delayed inflammatory reactions to tissue filler. Patients with a history of allergies, pre‐existing skin conditions or scheduled for filler injections should receive additional precounselling and monitoring. A better understanding of potential side‐effects may strengthen public confidence in those wary of new vaccine technologies.

show abstract

“…Recurrent HZ has been observed in chronic urticaria patients treated with cyclosporin-A after COVID-19 vaccination [73].…”

Section: Recurrent Hzmentioning

confidence: 99%

Herpes zoster: A Review of Clinical Manifestations and Management

Patil

Goldust

Wollina

2022

Viruses

180

123

View full text Add to dashboard Cite

The Varicella-zoster virus (VZV) or human herpes virus 3 is a neurotropic human alpha herpes virus responsible for chickenpox/varicella and shingles/herpes zoster (HZ). This review will focus on HZ. Since HZ is secondary to varicella, its incidence increases with age. In children and youngsters, HZ is rare and associated to metabolic and neoplastic disorders. In adults, advanced age, distress, other infections (such as AIDS or COVID-19), and immunosuppression are the most common risk factors. HZ reactivation has recently been observed after COVID-19 vaccination. The disease shows different clinical stages of variable clinical manifestations. Some of the manifestations bear a higher risk of complications. Among the possible complications, postherpetic neuralgia, a chronic pain disease, is one of the most frequent. HZ vasculitis is associated with morbidity and mortality. Renal and gastrointestinal complications have been reported. The cornerstone of treatment is early intervention with acyclovir or brivudine. Second-line treatments are available. Pain management is essential. For (secondary) prophylaxis, currently two HZV vaccines are available for healthy older adults, a live attenuated VZV vaccine and a recombinant adjuvanted VZV glycoprotein E subunit vaccine. The latter allows vaccination also in severely immunosuppressed patients. This review focuses on manifestations of HZ and its management. Although several articles have been published on HZ, the literature continues to evolve, especially in regard to patients with comorbidities and immunocompromised patients. VZV reactivation has also emerged as an important point of discussion during the COVID-19 pandemic, especially after vaccination. The objective of this review is to discuss current updates related to clinical presentations, complications, and management of HZ.

show abstract

Recurrent herpes zoster after COVID‐19 vaccination in patients with chronic urticaria being treated with cyclosporine—A report of 3 cases

Abstract: Recurrent herpes zoster after COVID-19 vaccination in patients with chronic urticaria being treated with cyclosporine-A report of 3 cases.

Cited by 21 publications

References 5 publications

Varicella-Zoster virus reactivation following severe acute respiratory syndrome coronavirus 2 vaccination or infection: New insights

Varicella-Zoster virus reactivation following severe acute respiratory syndrome coronavirus 2 vaccination or infection: New insights

Global prevalence and clinical manifestations of cutaneous adverse reactions following COVID‐19 vaccination: A systematic review and meta‐analysis

Herpes zoster: A Review of Clinical Manifestations and Management

Contact Info

Product

Resources

About